Bankruptcy
In writing literally hundreds of stories this year, two BioSpace writers, Alex Keown and Mark Terry, found certain stories particularly intriguing or impactful. Some of those were such big topics that they were covered over a series of stories. Looking back at 2018, here are their Top 10.
Theranos fit in with the opaque culture of Silicon Valley, which allowed it to thrive and amass a fortune without delivering anything, book argues.
New Partnership Will Improve Orange County’s Healthcare Services
Mississauga, Ontario-based Aralez Pharmaceuticals Inc. has entered into a stalking horse agreement to sell its assets to two separate companies, Nuvo Pharmaceuticals and Deerfield Management Companies. The beleaguered company will secure about $250 million for its assets from the sale as it files for bankruptcy.
The Cancer Prevention Institute of California (CPIC), located in Fremont, California, announced it was disbanding after 44 years. The reason for the closing, it indicates, is lack of federal funding.
Shares of weight-loss drugmaker Orexigen Therapeutics are in free-fall this morning after the company announced it filed for bankruptcy.
It’s the end of the road for Cambridge, MA based Enumeral Biomedical.
Arno Therapeutics is calling it quits. It sold off all its assets, with the final asset being the rights to Onapristone, which it sold to Context Biopharma.
As part of a portfolio update, Altas Ventures noted that Raze Therapeutics, a biotech launched in 2014, has closed its doors.
Dart will close its doors on Feb. 9 due to poor progress on its therapeutic goals and little return on hundreds of millions of dollars in R&D.
PRESS RELEASES